188 related articles for article (PubMed ID: 17380261)
1. New insight into the role of polyethylene glycol acting as protein release modifier in lipidic implants.
Herrmann S; Mohl S; Siepmann F; Siepmann J; Winter G
Pharm Res; 2007 Aug; 24(8):1527-37. PubMed ID: 17380261
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms controlling protein release from lipidic implants: effects of PEG addition.
Herrmann S; Winter G; Mohl S; Siepmann F; Siepmann J
J Control Release; 2007 Apr; 118(2):161-8. PubMed ID: 17275943
[TBL] [Abstract][Full Text] [Related]
3. A novel mathematical model quantifying drug release from lipid implants.
Siepmann F; Herrmann S; Winter G; Siepmann J
J Control Release; 2008 Jun; 128(3):233-40. PubMed ID: 18442866
[TBL] [Abstract][Full Text] [Related]
4. Lipid extrudates as novel sustained release systems for pharmaceutical proteins.
Schulze S; Winter G
J Control Release; 2009 Mar; 134(3):177-85. PubMed ID: 19121347
[TBL] [Abstract][Full Text] [Related]
5. Continuous release of rh-interferon alpha-2a from triglyceride matrices.
Mohl S; Winter G
J Control Release; 2004 May; 97(1):67-78. PubMed ID: 15147805
[TBL] [Abstract][Full Text] [Related]
6. Drug release from lipid-based implants: elucidation of the underlying mass transport mechanisms.
Guse C; Koennings S; Kreye F; Siepmann F; Goepferich A; Siepmann J
Int J Pharm; 2006 May; 314(2):137-44. PubMed ID: 16503388
[TBL] [Abstract][Full Text] [Related]
7. Continuous release of Rh-interferon (alpha-2a from triglyceride implants: storage stability of the dosage forms.
Mohl S; Winter G
Pharm Dev Technol; 2006 Feb; 11(1):103-10. PubMed ID: 16544914
[TBL] [Abstract][Full Text] [Related]
8. NIR spectroscopy-a non-destructive analytical tool for protein quantification within lipid implants.
Schönbrodt T; Mohl S; Winter G; Reich G
J Control Release; 2006 Aug; 114(2):261-7. PubMed ID: 16872710
[TBL] [Abstract][Full Text] [Related]
9. In situ precipitation and vacuum drying of interferon alpha-2a: development of a single-step process for obtaining dry, stable protein formulation.
Kumar V; Sharma VK; Kalonia DS
Int J Pharm; 2009 Jan; 366(1-2):88-98. PubMed ID: 18824225
[TBL] [Abstract][Full Text] [Related]
10. Drug release mechanisms of cast lipid implants.
Kreye F; Siepmann F; Willart JF; Descamps M; Siepmann J
Eur J Pharm Biopharm; 2011 Aug; 78(3):394-400. PubMed ID: 21352913
[TBL] [Abstract][Full Text] [Related]
11. Effect of drug solubility and lipid carrier on drug release from lipid nanoparticles for dermal delivery.
Zoubari G; Staufenbiel S; Volz P; Alexiev U; Bodmeier R
Eur J Pharm Biopharm; 2017 Jan; 110():39-46. PubMed ID: 27810471
[TBL] [Abstract][Full Text] [Related]
12. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
Jo YW; Youn YS; Lee SH; Kim BM; Kang SH; Yoo M; Choi EC; Lee KC
Int J Pharm; 2006 Feb; 309(1-2):87-93. PubMed ID: 16406701
[TBL] [Abstract][Full Text] [Related]
13. The influence of covalently linked and free polyethylene glycol on the structural and release properties of rhBMP-2 loaded microspheres.
Lochmann A; Nitzsche H; von Einem S; Schwarz E; Mäder K
J Control Release; 2010 Oct; 147(1):92-100. PubMed ID: 20603166
[TBL] [Abstract][Full Text] [Related]
14. Drug release from extruded solid lipid matrices: theoretical predictions and independent experiments.
Güres S; Siepmann F; Siepmann J; Kleinebudde P
Eur J Pharm Biopharm; 2012 Jan; 80(1):122-9. PubMed ID: 22008146
[TBL] [Abstract][Full Text] [Related]
15. Release pathways of interferon α2a molecules from lipid twin screw extrudates revealed by single molecule fluorescence microscopy.
Sax G; Feil F; Schulze S; Jung C; Bräuchle C; Winter G
J Control Release; 2012 Sep; 162(2):295-302. PubMed ID: 22820452
[TBL] [Abstract][Full Text] [Related]
16. Release mechanisms of acetaminophen from polyethylene oxide/polyethylene glycol matrix tablets utilizing magnetic resonance imaging.
Tajiri T; Morita S; Sakamoto R; Suzuki M; Yamanashi S; Ozaki Y; Kitamura S
Int J Pharm; 2010 Aug; 395(1-2):147-53. PubMed ID: 20580795
[TBL] [Abstract][Full Text] [Related]
17. Correlation of in vivo and in vitro release data for rh-INFalpha lipid implants.
Schwab M; Kessler B; Wolf E; Jordan G; Mohl S; Winter G
Eur J Pharm Biopharm; 2008 Oct; 70(2):690-4. PubMed ID: 18582576
[TBL] [Abstract][Full Text] [Related]
18. [Interferon alpha-2b modified with polyethylene glycol].
Wu Y; Zhai Y; Lei J; Ma G; Su Z
Sheng Wu Gong Cheng Xue Bao; 2008 Sep; 24(9):1658-63. PubMed ID: 19160853
[TBL] [Abstract][Full Text] [Related]
19. Role of a novel excipient poly(ethylene glycol)-b-poly(L-histidine) in retention of physical stability of insulin at aqueous/organic interface.
Taluja A; Bae YH
Mol Pharm; 2007; 4(4):561-70. PubMed ID: 17439239
[TBL] [Abstract][Full Text] [Related]
20. Stability of bovine serum albumin complexed with PEG-poly(L-histidine) diblock copolymer in PLGA microspheres.
Kim JH; Taluja A; Knutson K; Han Bae Y
J Control Release; 2005 Dec; 109(1-3):86-100. PubMed ID: 16266769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
